Principal Financial Group Inc. bought a new stake in Wave Life Sciences Ltd. (NASDAQ:WVE – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 248,645 shares of the company’s stock, valued at approximately $3,076,000. Principal Financial Group Inc. owned about 0.16% of Wave Life Sciences at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in WVE. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after acquiring an additional 856 shares in the last quarter. KBC Group NV purchased a new position in shares of Wave Life Sciences in the fourth quarter valued at $67,000. Point72 DIFC Ltd purchased a new position in shares of Wave Life Sciences in the third quarter valued at $98,000. Orion Portfolio Solutions LLC purchased a new position in Wave Life Sciences during the third quarter worth about $123,000. Finally, XTX Topco Ltd purchased a new position in Wave Life Sciences during the third quarter worth about $126,000. Institutional investors and hedge funds own 89.73% of the company’s stock.
Wave Life Sciences Stock Performance
Shares of NASDAQ WVE opened at $11.23 on Wednesday. The company has a market cap of $1.71 billion, a P/E ratio of -10.12 and a beta of -1.09. The firm’s fifty day moving average is $11.63 and its two-hundred day moving average is $11.19. Wave Life Sciences Ltd. has a 52-week low of $4.25 and a 52-week high of $16.74.
Analyst Upgrades and Downgrades
Read Our Latest Report on Wave Life Sciences
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Read More
- Five stocks we like better than Wave Life Sciences
- Which Wall Street Analysts are the Most Accurate?
- GitLab: Get In While It’s Down—Big Rebound Ahead
- How to Use the MarketBeat Stock Screener
- Tesla Stock: Finding a Bottom May Take Time
- What is a Low P/E Ratio and What Does it Tell Investors?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.